Rate of Switching from Regeneron’s Eylea to Genentech’s Vabysmo Doubled Over Past Year for Diabetic Macular Edema
01 nov. 2023 14h55 HE
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 01, 2023 (GLOBE NEWSWIRE) -- As U.S. ophthalmologists increasingly embrace a wider array of treatment options, the landscape of the diabetic macular edema (DME) market has...
Aeroflow Healthcare Celebrates Success in its Home State with the Passage of North Carolina’s Breast Pump Tax Exemption
01 nov. 2023 09h00 HE
|
Aeroflow Healthcare
Aeroflow Healthcare worked with state leaders Rep. Tricia Cotham and Senator Paul Newton to push this legislation forward.
U.S. Department of Energy, Sunvapor and Oberon Fuels Aim to Unlock Zero-Emission Renewable Fuel Production with Test of Novel Solar Steam & Battery Technology
13 juin 2023 09h01 HE
|
Oberon Fuels
Demonstration project will replace natural gas with zero-emission solar energy for production of Oberon’s rDME® fuel SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- The U.S. Department of Energy is...
DCC Energy and Oberon Fuels to Boost Renewable Dimethyl Ether Production to Reduce Emissions of European LPG Market
29 mars 2023 07h00 HE
|
Oberon Fuels
SAN DIEGO and DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- DCC plc, the leading international sales, marketing and support services group, has partnered with Oberon Fuels, the leading...
ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial
08 mars 2023 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., March 08, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics to Present at the XXVth Biennial Meeting of the International Society for Eye Research
13 févr. 2023 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 13, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics to Present at 2023 BIO CEO & Investor Conference
02 févr. 2023 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 02, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for ONL1204 Ophthalmic Solution
01 févr. 2023 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 01, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics to Highlight New Data in Upcoming Scientific Presentations at the 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research
26 janv. 2023 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Jan. 26, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
Durable Medical Equipment (DME) Market will Revenue to Cross US$ 282900 million in 2022 to 2028 Research by Business Opportunities, Top Companies report covers, Market-specific challenges, consumption by Regional data
17 oct. 2022 08h39 HE
|
Proficient Market Insights
PUNE, Oct. 17, 2022 (GLOBE NEWSWIRE) -- "Durable Medical Equipment (DME) Market" | No. of pages: 87| research report focus on overall information that can help to take decisions on current market...